Roche and Eli Lilly and Co are joining forces to develop a blood test for Alzheimer's disease, and plan to kick off a two-year clinical trial involving hundreds of volunteers with the aim of winning U.S. regulatory approval. The effort, unveiled in a statement on Wednesday, comes as Lilly as well as Eisai and Biogen are gearing up to sell drugs aimed at slowing the advance of the mind-robbing illness, but their use will require a diagnosis at earlier disease stages than is the norm today. Roche Holding AG would recruit several hundred volunteers with early signs of dementia over the next 18 to 24 months with trial data potentially ready for a U.S. regulatory filing in 2025, Bruce Jordan, leader of Personalized Healthcare Solutions at Roche Diagnostics, told Reuters.
Eli Lilly (LLY) closed the most recent trading day at $331.08, moving -0.76% from the previous trading session.
The Dow Jones Industrial Average consists of 30 such businesses. A $10,000 investment made 10 years ago, with dividends reinvested along the way, would now be worth $76,000. Unsurprisingly, the company's status as a leading pharmaceutical company is supported by an exceptionally strong portfolio of products.